ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

JCR Pharmaceuticals Co., Ltd.

Business Summary

JCR Pharmaceuticals Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following segments: Pharmaceutical Business; and Medical and Research Equipment Business. The Pharmaceutical Business segment deals with the manufacture, purchase, and sale of ethical drugs, active pharmaceutical ingredients, and raw materials. The Medical and Research Equipment Business segment sells medical devices and laboratory equipment. The company was founded by Shin Ashida on September 13, 1975 and is headquartered in Ashiya, Japan.

Financial Highlights

Mar 2022 JPYUSD
Revenue51,082M454.57M
Gross Profit40,621M361.48M
Operating income19,935M177.40M
Income before tax19,404M172.67M
Net income14,507M129.09M
EBITDA21,880M194.70M
Diluted EPS116.791.03
Dividends Per Share220.19
Total Assets97,477M803.10M
Total liabilities46,387M382.17M
Total equity50,884M419.22M
Operating cash flow9,289M82.66M
Currency in JPYCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 20,594M 23,160M 24,781M 30,085M 51,082M
Gross Profit 14,466M 16,593M 16,880M 22,273M 40,621M
Operating income 3,785M 4,968M 3,245M 8,270M 19,935M
Income before tax 3,895M 4,928M 3,422M 8,653M 19,404M
Net income 3,069M 3,714M 2,678M 6,892M 14,507M
EBITDA 5,167M 6,311M 4,679M 10,162M 21,880M
Diluted EPS 24.52 29.98 21.58 55.52 116.79
Dividends Per Share 6.50 7.50 8 12 22
Total Assets 38,737M 42,956M 48,118M 74,162M 97,477M
Total liabilities 11,206M 12,079M 15,537M 35,604M 46,387M
Total equity 27,343M 30,685M 32,390M 38,383M 50,884M
Operating cash flow 3,133M 3,905M 4,927M 10,341M 9,289M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 185.81M 208.84M 227.92M 283.66M 454.57M
Gross Profit 130.52M 149.62M 155.25M 210.00M 361.48M
Operating income 34.15M 44.79M 29.84M 77.97M 177.40M
Income before tax 35.14M 44.43M 31.47M 81.58M 172.67M
Net income 27.69M 33.49M 24.63M 64.98M 129.09M
EBITDA 46.61M 56.90M 43.03M 95.81M 194.70M
Diluted EPS 0.22 0.27 0.19 0.52 1.03
Dividends Per Share 0.05 0.06 0.07 0.11 0.19
Total Assets 364.24M 388.09M 445.72M 671.14M 803.10M
Total liabilities 105.36M 109.12M 143.92M 322.20M 382.17M
Total equity 257.10M 277.22M 300.03M 347.35M 419.22M
Operating cash flow 28.26M 35.21M 45.31M 97.50M 82.66M

Valuation Measures

Mar 2022
PER19.24
ROA16.90%
ROE32.50%
Operating margin39.02%
Profit margin28.39%

Key executives

  • Chairman & President: Shin Ashida
  • MD, GM-Research & Head-Corporate Strategy: Hiroyuki Sonoda
  • Executive Officer & General Manager-Research: Toru Hirado
  • Executive Officer & Manager-Overseas Business: Takayo Egawa
  • Senior Executive Officer & GM-Administration: Yutaka Honda

Shareholders

  • Medipal Holdings Corp. (22.4%)
  • Kissei Pharmaceutical Co., Ltd. (7.9%)
  • ASHIDA FAMILY (7.6%)
  • JCR Pharmaceuticals Co., Ltd. (4.3%)
  • ASHIDA SHIN (3.6%)
  • Sumitomo Pharma Co., Ltd. (2.6%)
  • Nomura Asset Management Co., Ltd. (1.9%)
  • Mochida Pharmaceutical Co., Ltd. (1.6%)
  • The Vanguard Group, Inc. (1.0%)
  • JCR Pharmaceuticals Employee Stock Ownership Plan (0.8%)

Contact Details

Related Companies

  • JCR International SA
  • Jcr Pharmaceuticals Employee Incentive Plan
  • JCR Pharmaceuticals Employee Stock Ownership Plan
  • Dainippon Sumitomo Pharma Co. Ltd. /HGH Business/
  • ArmaGen, Inc.

Competitors

  • BioMarin Pharmaceutical Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Lysogene SA
  • Ascendis Pharma A/S Sponsored ADR
  • Orchard Therapeutics Plc Sponsored ADR
  • Sigilon Therapeutics, Inc.
  • REGENXBIO, Inc.
  • SCM LIFESCIENCE CO., LTD
  • Inventiva SA
  • Denali Therapeutics Inc.
  • Aptamer Sciences, Inc.
  • CORESTEM INC.
Last Updated on 16 Aug, 2022

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more